logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11034691 B1

PDFFull Text
Date of Patent:
Jun. 15, 2021

Filed:

Jun. 11, 2019

Sphinogosine-1 -phosphate receptor modulators for treatment of cardiopulmonary disorders

Applicant:

The Scripps Research Institute, La Jolla, CA (US);

Inventors:

Edward Roberts, Fallbrook, CA (US);

Hugh Rosen, La Jolla, CA (US);

Mariangela Urbano, Del Mar, CA (US);

Miguel Guerrero, San Diego, CA (US);

Assignee:

THE SCRIPPS RESEARCH INSTITUTE, La Jolla, CA (US);

Attorney:

Schwegman Lundberg & Woessner, P.A.

Primary Examiner:

Kristin A Vajda

Int. Cl.
CPC ...
C07D 471/04 (2006.01); C07D 239/26 (2006.01); C07D 213/78 (2006.01); C07D 241/42 (2006.01); C07D 249/08 (2006.01); C07D 263/32 (2006.01); C07D 271/10 (2006.01); C07D 413/14 (2006.01); C07D 213/38 (2006.01); C07D 213/55 (2006.01); C07D 213/61 (2006.01); C07D 213/75 (2006.01); C07D 213/80 (2006.01); C07D 215/12 (2006.01); C07D 217/18 (2006.01); C07D 235/14 (2006.01); C07D 237/08 (2006.01); C07D 239/30 (2006.01); C09B 55/00 (2006.01); C07D 213/40 (2006.01); C07D 211/16 (2006.01); C07D 285/12 (2006.01); C07D 271/06 (2006.01); C07D 413/12 (2006.01); C07D 413/06 (2006.01); C07D 413/04 (2006.01); C07D 409/12 (2006.01); C07D 405/12 (2006.01); C07D 405/06 (2006.01); C07D 401/12 (2006.01); C07D 333/20 (2006.01); C07D 309/14 (2006.01); C07D 309/06 (2006.01); C07D 241/16 (2006.01); C07D 263/58 (2006.01); C07C 255/63 (2006.01);
U.S. Cl.
CPC ...
C07D 471/04 (2013.01); C07C 255/63 (2013.01); C07D 211/16 (2013.01); C07D 213/38 (2013.01); C07D 213/40 (2013.01); C07D 213/55 (2013.01); C07D 213/61 (2013.01); C07D 213/75 (2013.01); C07D 213/78 (2013.01); C07D 213/80 (2013.01); C07D 215/12 (2013.01); C07D 217/18 (2013.01); C07D 235/14 (2013.01); C07D 237/08 (2013.01); C07D 239/26 (2013.01); C07D 239/30 (2013.01); C07D 241/16 (2013.01); C07D 241/42 (2013.01); C07D 249/08 (2013.01); C07D 263/32 (2013.01); C07D 263/58 (2013.01); C07D 271/06 (2013.01); C07D 271/10 (2013.01); C07D 285/12 (2013.01); C07D 309/06 (2013.01); C07D 309/14 (2013.01); C07D 333/20 (2013.01); C07D 401/12 (2013.01); C07D 405/06 (2013.01); C07D 405/12 (2013.01); C07D 409/12 (2013.01); C07D 413/04 (2013.01); C07D 413/06 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C09B 55/002 (2013.01); C09B 55/005 (2013.01); C09B 55/007 (2013.01);
Abstract

The invention provides compounds effective as sphingosine-1-phosphate receptor modulators for treatment of cardiopulmonary diseases, such as hypertension (including malignant hypertension), angina, myocardial infarction, cardiac arrhythmias, congestive heart failure, coronary heart disease, atherosclerosis, angina pectoris, dysrhythmias, cardiomyothopy (including hypertropic cardiomyothopy), heart failure, cardiac arrest, bronchitis, asthma, chronic obstructive pulmonary disease, cystic fibrosis, croup, emphysema, pleurisy, pulmonary fibrosis, pneumonia, pulmonary embolus, pulmonary hypertension, mesothelioma, ventricular conduction abnormalities, complete heart block, adult respiratory distress syndrome, sepsis syndrome, idiopathic pulmonary fibrosis, scleroderma, systemic sclerosis, retroperitoneal fibrosis, prevention of keloid formation, or cirrhosis.

Find Patent Forward Citations

Loading…